Aptevo Therapeutics Inc. SEC filings APVO
Aptevo Therapeutics Inc. has 740 filings in SEC EDGAR's recent list, going back to Apr 15, 2016. Its latest annual report, Form ARS, was filed on Jul 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Aug 31, 2026 | Sep 22, 2026 |
| PRE 14A | Preliminary proxy statement | Aug 21, 2026 | Aug 21, 2026 |
| DEF 14A | Proxy statement | Jul 31, 2026 | Jul 31, 2026 |
| DEF 14A | Proxy statement | Jan 26, 2026 | Jan 23, 2026 |
| PRE 14A | Preliminary proxy statement | Jan 16, 2026 | Jan 16, 2026 |
| DEF 14A | Proxy statement | Jul 3, 2025 | Jul 24, 2025 |
| PRE 14A | Preliminary proxy statement | Jun 23, 2025 | Jul 24, 2025 |
| DEF 14A | Proxy statement | Apr 25, 2025 | May 14, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 10, 2025 | May 9, 2025 |
| DEF 14A | Proxy statement | Oct 3, 2024 | Oct 25, 2024 |
| PRE 14A | Preliminary proxy statement | Sep 23, 2024 | Oct 25, 2024 |
| DEF 14A | Proxy statement | Jul 15, 2024 | Aug 6, 2024 |
| PRE 14A | Preliminary proxy statement | Jul 3, 2024 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 23, 2024 | — |
| DEF 14A | Proxy statement | Apr 23, 2024 | Dec 31, 2023 |
| DEF 14A | Proxy statement | Dec 22, 2023 | Dec 22, 2023 |
| PRE 14A | Preliminary proxy statement | Dec 12, 2023 | Dec 13, 2023 |
| DEFA14A | Additional proxy material | Apr 19, 2023 | — |
| DEF 14A | Proxy statement | Apr 18, 2023 | Jun 2, 2023 |
| DEF 14A | Proxy statement | Apr 27, 2022 | Jun 7, 2022 |
| DEFA14A | Additional proxy material | Jun 21, 2021 | — |
| DEFA14A | Additional proxy material | Mar 31, 2021 | — |
| DEFA14A | Additional proxy material | Mar 31, 2021 | — |
| DEFA14A | Additional proxy material | Feb 10, 2021 | — |
| DEF 14A | Proxy statement | Apr 20, 2020 | May 27, 2020 |
| PRE 14A | Preliminary proxy statement | Apr 9, 2020 | May 27, 2020 |
| DEF 14A | Proxy statement | Feb 11, 2020 | Mar 11, 2020 |
| PRE 14A | Preliminary proxy statement | Jan 31, 2020 | Mar 11, 2020 |
| DEFA14A | Additional proxy material | Apr 5, 2019 | — |
| DEF 14A | Proxy statement | Apr 5, 2019 | May 15, 2019 |
| DEFA14A | Additional proxy material | Apr 20, 2018 | — |
| DEF 14A | Proxy statement | Apr 20, 2018 | Jun 1, 2018 |
| DEFA14A | Additional proxy material | Apr 14, 2017 | — |
| DEF 14A | Proxy statement | Apr 14, 2017 | May 31, 2017 |
Showing 34 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- APVO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Seattle, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1671584
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.